From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies

SETting OP449 into the PP2A-Activating Drug Family

(2014) P. Neviani et al.   CLINICAL CANCER RESEARCH

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond

(2014) Christopher S. Garris et al.   IMMUNOLOGY

Clinical implications of theSETBP1mutation in patients with primary myelodysplastic syndrome and its stability during disease progression

(2013) Hsin-An Hou et al.   AMERICAN JOURNAL OF HEMATOLOGY

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

(2013) J. J. Oaks et al.   BLOOD

PP2ACdc55regulates G1cyclin stability

(2013) Paula McCourt et al.   CELL CYCLE

New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia

(2013) Eric C. Hales et al.   CELLULAR SIGNALLING

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations

(2013) M Meggendorfer et al.   LEUKEMIA

BCR/ABL1-positive acute lymphoblastic leukemia relapsing asBCR/ABL1-negative acute lymphoblastic leukemia

(2013) Lara Rizzotto et al.   LEUKEMIA & LYMPHOMA

Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA–mRNA interactions

(2013) Hyun Min Jung et al.   MOLECULAR BIOLOGY OF THE CELL

Somatic SETBP1 mutations in myeloid malignancies

(2013) Hideki Makishima et al.   NATURE GENETICS

The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity

(2013) Adam Collison et al.   NATURE MEDICINE

miR-29 Acts as a Decoy in Sarcomas to Protect the Tumor Suppressor A20 mRNA from Degradation by HuR

(2013) M. Y. Balkhi et al.   Science Signaling

PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis

(2013) X Cheng et al.   Blood Cancer Journal

Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

(2013) Anni Laine et al.   Cancer Discovery

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

(2012) Sahar A. Saddoughi et al.   EMBO Molecular Medicine

PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates

(2012) Alison Kurimchak et al.   GENE

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

(2012) Rocco Piazza et al.   NATURE GENETICS

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

(2011) L. Alinari et al.   BLOOD

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

(2011) D. J. Christensen et al.   BLOOD

Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A

(2011) A. Salas et al.   BLOOD

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

(2011) C. M. Lucas et al.   BLOOD

Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

(2011) Jens Ingwersen et al.   CLINICAL IMMUNOLOGY

CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation

(2011) J. WANG et al.   International Journal of Laboratory Hematology

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

In Search of CML Stem Cells’ Deadly Weakness

(2011) Francesca Pellicano et al.   Current Hematologic Malignancy Reports

Current Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

(2011) A. K. Fielding   Hematology-American Society of Hematology Education Program

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts

(2010) Anna M. Eiring et al.   CELL

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

(2010) Q. Liu et al.   CLINICAL CANCER RESEARCH

MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors

(2010) Xi Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia

(2010) Konstantinos J. Mavrakis et al.   NATURE CELL BIOLOGY

De novo mutations of SETBP1 cause Schinzel-Giedion syndrome

(2010) Alexander Hoischen et al.   NATURE GENETICS

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Search for New Particles in Two-Jet Final States in 7 TeV Proton-Proton Collisions with the ATLAS Detector at the LHC

(2010) G. Aad et al.   PHYSICAL REVIEW LETTERS

Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes

(2009) G. A. Calin et al.   BLOOD

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

SnapShot: MicroRNAs in Cancer

(2009) Riccardo Spizzo et al.   CELL

MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer

(2009) Anchit Khanna et al.   JNCI-Journal of the National Cancer Institute

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Nm23-H1 regulates the proliferation and differentiation of the human chronic myeloid leukemia K562 cell line: A functional proteomics study

(2009) Lin Jin et al.   LIFE SCIENCES

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Protein phosphatase 2A regulatory subunits and cancer

(2008) Pieter J.A. Eichhorn et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia

(2008) P. Van Vlierberghe et al.   BLOOD

Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding

(2008) X. Deng et al.   BLOOD

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

(2008) Danilo Perrotti et al.   CANCER AND METASTASIS REVIEWS

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

(2008) Krzysztof Mrózek et al.   CURRENT OPINION IN ONCOLOGY

PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail)

(2008) Veerle Janssens et al.   TRENDS IN BIOCHEMICAL SCIENCES

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE